MX2022012135A - Métodos para tratar la enfermedad de coronavirus de 2019. - Google Patents

Métodos para tratar la enfermedad de coronavirus de 2019.

Info

Publication number
MX2022012135A
MX2022012135A MX2022012135A MX2022012135A MX2022012135A MX 2022012135 A MX2022012135 A MX 2022012135A MX 2022012135 A MX2022012135 A MX 2022012135A MX 2022012135 A MX2022012135 A MX 2022012135A MX 2022012135 A MX2022012135 A MX 2022012135A
Authority
MX
Mexico
Prior art keywords
methods
inhibitor
coronavirus disease
treating coronavirus
treating
Prior art date
Application number
MX2022012135A
Other languages
English (en)
Inventor
Michael Steven Vincent
Michael Corbo
Spencer Ian Danto
Tamas Koncz
Elena Peeva
Hernan Valdez
Cara Margaret May Williams
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2022012135A publication Critical patent/MX2022012135A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se relaciona con el descubrimiento de nuevos métodos para tratar la respuesta inflamatoria patológica asociada con pacientes infectados con SARS-CoV-2 que comprende administrar vía oral al paciente en necesidad de tal tratamiento una cantidad terapéuticamente efectiva de un inhibidor de JAK, un inhibidor de JAK/TYK o un inhibidor de IRAK4 o una combinación de los mismos.
MX2022012135A 2020-04-04 2021-04-01 Métodos para tratar la enfermedad de coronavirus de 2019. MX2022012135A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063005303P 2020-04-04 2020-04-04
US202063018828P 2020-05-01 2020-05-01
US202163162600P 2021-03-18 2021-03-18
US202163164616P 2021-03-23 2021-03-23
PCT/IB2021/052749 WO2021198980A1 (en) 2020-04-04 2021-04-01 Methods of treating coronavirus disease 2019

Publications (1)

Publication Number Publication Date
MX2022012135A true MX2022012135A (es) 2023-01-18

Family

ID=75478097

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012135A MX2022012135A (es) 2020-04-04 2021-04-01 Métodos para tratar la enfermedad de coronavirus de 2019.

Country Status (12)

Country Link
US (1) US20230149407A1 (es)
EP (1) EP4125900A1 (es)
JP (1) JP2023519738A (es)
KR (1) KR20220164008A (es)
CN (1) CN115715194A (es)
AU (1) AU2021248720A1 (es)
BR (1) BR112022020020A2 (es)
CA (1) CA3177852A1 (es)
IL (1) IL297050A (es)
MX (1) MX2022012135A (es)
WO (1) WO2021198980A1 (es)
ZA (1) ZA202210984B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115385983A (zh) * 2022-01-11 2022-11-25 嘉兴安谛康生物科技有限公司 氮杂双环类化合物及其制备方法、药物组合物和用途
WO2023192114A1 (en) * 2022-03-31 2023-10-05 Alexion Pharmaceuticals, Inc. Compositions and methods for preventing and treating cytokine release syndrome
CN117838689A (zh) * 2024-01-09 2024-04-09 暨南大学 培菲替尼在制备治疗流感病毒感染的药物中的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL218519B1 (pl) 1999-12-10 2014-12-31 Pfizer Prod Inc Związki pirolo [2,3-d] pirymidynowe, środek farmaceutyczny zawierający te związki oraz ich zastosowanie
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
GT200200234A (es) 2001-12-06 2003-06-27 Compuestos cristalinos novedosos
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
RU2604062C2 (ru) 2010-07-13 2016-12-10 Ф.Хоффманн-Ля Рош Аг ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА И ТИЕНО[3,2-b]ПИРИМИДИНА В КАЧЕСТВЕ МОДУЛЯТОРОВ IRAK-4
US9586948B2 (en) 2012-10-08 2017-03-07 Merck Sharp & Dohme Corp. Inhibitors of IRAK4 activity
EP2903617B1 (en) 2012-10-08 2019-01-30 Merck Sharp & Dohme Corp. Inhibitors of irak4 activity
JP6145179B2 (ja) 2013-02-22 2017-06-07 ファイザー・インク ヤヌス関連キナーゼ（ＪＡＫ）の阻害剤としてのピロロ［２，３−ｄ］ピリミジン誘導体
WO2014143672A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Macrocyclic compounds as irak4 inhibitors for the treatment of inflammatory diseases
JP6192839B2 (ja) 2013-12-05 2017-09-06 ファイザー・インク ピロロ［２，３−ｄ］ピリミジニル、ピロロ［２，３−ｂ］ピラジニル、およびピロロ［２，３−ｄ］ピリジニルアクリルアミド
US10160753B2 (en) 2014-01-10 2018-12-25 Aurigene Discovery Technologies Limited Indazole compounds as IRAK4 inhibitors
LT3805233T (lt) 2014-01-13 2024-05-10 Aurigene Oncology Limited N-(5-(3-hidroksipirolidin-1-il)-2-morfolinooksazolo[4,5-b]piridin-6-il)-2-(2- metilpiridin-4-il)oksazol-karboksamido (r) ir (s) enantiomerai, kaip irak4 inhibitoriai, skirti vėžio gydymui
RS58597B1 (sr) 2014-04-04 2019-05-31 Pfizer Biciklično-spojena heteroaril ili aril jedinjenja i njihova upotreba kao irak4 inhibitora
MX2016014642A (es) 2014-05-09 2017-05-25 Kineta Inc Compuestos y composiciones farmaceuticas antivirales, asi como metodos de uso de los mismos.
US10246456B2 (en) 2014-07-18 2019-04-02 Biogen Ma Inc. IRAK4 inhibiting agents
NO2721710T3 (es) 2014-08-21 2018-03-31
US9969749B2 (en) 2014-09-30 2018-05-15 Merck Sharp & Dohme Corp. Inhibitors of IRAK4 activity
WO2016053769A1 (en) 2014-09-30 2016-04-07 Merck Sharp & Dohme Corp. Inhibitors of irak4 activity
EP3200790B1 (en) 2014-09-30 2020-08-26 Merck Sharp & Dohme Corp. Inhibitors of irak4 activity
EP3200789B1 (en) 2014-09-30 2019-11-06 Merck Sharp & Dohme Corp. Inhibitors of irak4 activity
CR20170309A (es) 2014-12-05 2018-02-02 Celgene Corp Pirazolo [1,5-a] pirazinas 4,6-sustituidas como inhibidores de janus cinasas
WO2016144848A1 (en) 2015-03-12 2016-09-15 Merck Sharp & Dohme Corp. Pyrrolotriazine inhibitors of irak4 activity
WO2016144846A1 (en) 2015-03-12 2016-09-15 Merck Sharp & Dohme Corp. Pyrazolopyrimidine inhibitors of irak4 activity
WO2016144847A1 (en) 2015-03-12 2016-09-15 Merck Sharp & Dohme Corp. Pyrrolopyridazine inhibitors of irak4 activity
US10155765B2 (en) 2015-03-12 2018-12-18 Merck Sharp & Dohme Corp. Carboxamide inhibitors of IRAK4 activity
KR102048719B1 (ko) 2015-08-13 2019-11-26 베이징 한미 파마슈티컬 컴퍼니 리미티드 Irak4억제제 및 이의 용도
SI3341367T1 (sl) 2015-08-27 2021-05-31 Pfizer Inc. Biciklične kondenzirane heteroarilne ali arilne sestavine kot modulatorji IRAK-4
AU2017222417B2 (en) 2016-02-24 2020-07-09 Pfizer Inc. Pyrazolo[1,5-a]pyrazin-4-yl derivatives as JAK-inhibitors
US10059708B2 (en) 2016-04-26 2018-08-28 Northwestern University Therapeutic targeting of the interleukin 1 receptor-associated kinase 4 (IRAK4) in leukemias characterized by rearrangements in the mixed lineage leukemia gene (MLL-r)
CN110951756B (zh) * 2020-02-23 2020-08-04 广州恩宝生物医药科技有限公司 表达SARS-CoV-2病毒抗原肽的核酸序列及其应用

Also Published As

Publication number Publication date
EP4125900A1 (en) 2023-02-08
US20230149407A1 (en) 2023-05-18
WO2021198980A1 (en) 2021-10-07
BR112022020020A2 (pt) 2022-11-22
AU2021248720A1 (en) 2022-11-03
KR20220164008A (ko) 2022-12-12
ZA202210984B (en) 2023-06-28
IL297050A (en) 2022-12-01
JP2023519738A (ja) 2023-05-12
CN115715194A (zh) 2023-02-24
CA3177852A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
MX2022012135A (es) Métodos para tratar la enfermedad de coronavirus de 2019.
MY196455A (en) Nitrile-Containing Compounds Useful as Antiviral Agents for The Treatment of a Coronavirus Infection
CR20210563A (es) Compuestos y métodos para el tratamiento de covid-19
MX2020007633A (es) Péptidos macrocíclicos contra acinetobacter baumannii.
EA201490163A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
TW200616608A (en) Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
EA201490277A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
NO20076245L (no) Anvendelse av TFPI for a behandle alvorlige bakterieinfeksjoner
BR0111591A (pt) Compostos, composição farmacêutica, e, métodos para elevar o nìvel de plasma do hormÈnio de crescimento em um mamìfero, para o tratamento de deficiência da secreção do hormÈnio de crescimento, para o tratamento do retardo do crescimento em crianças, para o tratamento de distúrbios metabólicos associados com a deficiência da secreção do hormÈnio de crescimento, em particular em pacientes idosos, e para promover a cura de ferimentos, recupeção de cirurgia ou recuperação de doenças debilitantes
NZ517038A (en) Use of serotonin reuptake inihibitor in medicaments for treating sexual dysfunction
ATE390928T1 (de) Zusammensetzungen zur behandlung von hauterkrankungen
EA202190569A1 (ru) Способы лечения болезни фабри у пациентов, имеющих мутацию в гене gla
EA202190544A1 (ru) Применение распадающихся в полости рта таблеток рилузола для лечения заболеваний
AR114392A1 (es) Tratamiento de pacientes con enfermedad de fabry clásica
PH12020551911A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
MX2022015554A (es) Moduladores de molecula peque?a de interleucina 17 (il-17).
MX2022006333A (es) Compuesto triheterociclico como inhibidor de jak y uso del mismo.
MX2023005563A (es) Profilaxis y tratamiento del angioedema.
EA202000347A1 (ru) ПРОТИВО-SARS-CoV-2 ВИРУСНОЕ СРЕДСТВО АНТИПРОВИР
AR127533A1 (es) INHIBIDORES DEL SARS-CoV-2 PARA EL TRATAMIENTO DE INFECCIONES POR CORONAVIRUS
MA53372B1 (fr) Pyridopyrimidinones comme inhibiteurs du récepteur h4 de l'histamine
EA202193190A1 (ru) Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов
WO2022023533A3 (en) Antiviral use of liraglutide and gefitinib
NO20032006D0 (no) Anvendelse av melagatran for fremstilling av et medikament for behandling av ischemiske lidelser
BR112022019858A2 (pt) Métodos de tratamento de esclerose sistêmica